Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

0.5350 +0.0550 (+11.46%)
Streaming Delayed Price Updated: 1:43 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Optinose Inc

< Previous 1 2 3 4 5 Next >
Recap: OptiNose Q1 Earnings
Via Benzinga
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
OptiNose's Return On Capital Employed Insights
Via Benzinga
Earnings Preview: OptiNose
Via Benzinga
OptiNose: Q2 Earnings Insights
  OptiNose (NASDAQ:OPTN) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Shared Additional Encouraging Data From Late-Stage Chronic Sinusitis Studies
Via Benzinga
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces CEO Transition and Business Update
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors 
From Optinose, Inc.
Via GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Departure of Acting Chief Financial Officer
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
Optinose Announces Proposed Public Offering of Common Stock and Warrants
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
From Optinose, Inc.
Via GlobeNewswire
Pooled Data Show Optinose's XHANCE Cut Sinusitis Flares By 66%
Optinose Inc (NASDAQ: OPTN) announced the results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for chronic sinusitis.  
Via Benzinga
Looking Into OptiNose's Return On Capital Employed
Benzinga Pro data, OptiNose (NASDAQ:OPTN) reported Q1 sales of $14.76 million. Earnings fell to a loss of $25.33 million, resulting in a 62.14% decrease from last quarter. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.